Indolizine: In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia
Mahaur Sangeeta1*, Upadhyay Sukirti Dr.2*, Pal Ravi Raj3*
1Department of Pharmaceutical Sciences, IFTM University, Moradabad, 244001, Uttar PradeshIndia.
2Associate Professor, Department of Pharmaceutical Sciences, IFTM University, Moradabad, 244001, Uttar PradeshIndia.
3Dyaynand Dinanath College, Institute of Pharmacy, National Highway 86, Ramaipur, Kanpur, Uttar Pradesh209214, U.P.India.
*Corresponding Author E-mail: firstname.lastname@example.org
Online published on 10 February, 2021.
Unusual and rapid reproductions of oncogene BCR-ABL protein in the stem cells has been established as the major cause of Chronic Myeloid Leukemia. It has been recognized that tyrosine kinase province of BCR-ABL protein is a possible healing target for the action of Chronic Myeloid Leukemia. First generation drug Imatinib could impede the enzymatic action by impeding the ATP binding with BCR-ABL protein. Second generation drugs Bosutinib, Nilotinib, Dasatinib, Ponatinib, Bafetinib can also against the mutated province of ABL tyrosine kinase protein. The purpose of the present study was to virtually screen the Indolizine databases compound library downloaded. The structure-based virtual screening on BCR-ABL was downloaded from protein data bank. The exhaustive docking approach on BCR-ABL has been performed using simple precision and extra precision mode and the findings of most potent compounds have been evaluated for their absorption, distribution, metabolism and excretion.
BCR-ABL protein, CML, Tyrosine Kinase, Indolizine..